Clinical Trial

Challenge Non-Typhoidal Salmonella (CHANTS) Study

Study acronym: CHANTS
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 2, 2025 (before its estimated February 28, 2026 completion). Its status may not reflect the trial's current state.
Summary
This protocol describes the challenge non-typhoidal Salmonella (CHANTS) study. This is a first-in-human phase 1, double-blinded, randomised, dose-escalation human infection study, conducted in healthy volunteers aged 18 to 50 years. The primary objective of the study is to perform a dose escalation with two strains (ST19 or ST313) to determine the infectious dose required for 60-75% of volunteers to develop Salmonellosis using a composite diagnostic criterion. The secondary objectives of the study are to describe and compare the clinical and laboratory features following controlled human infection. It is hoped that the successful establishment of an NTS human challenge model can be used in the future to test candidate vaccines for NTS disease.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-05-11; most recent amendment 2025-04-30.
Status change: Recruiting → Active, Not Recruiting 2025-04-30
Status change: Not Yet Recruiting → Recruiting 2023-12-07
Trial Details
NCT Number NCT05870150
Lead Sponsor Imperial College Healthcare NHS Trust
Collaborators: University of Oxford, University of Liverpool, PATH, Imperial College London
Conditions Salmonella Infections, Salmonella Typhimurium, Non-typhoidal Salmonella (NTS), Invasive Non-Typhoidal Salmonella Disease, Communicable Disease, Infections, Bacterial, Enteric Fever (Not Typhoid), Gastroenteritis
Enrollment 80 participants
Start Date 2023-08-31
Primary Completion 2026-02-28 (estimated)
Study Completion 2026-02-28 (estimated)
Updated on ClinicalTrials.gov 2025-05-02